AI-generated summary
The authors report a randomized trial in children with hematologic cancers receiving methotrexate chemotherapy, testing photobiomodulation for prevention and photodynamic therapy with indocyanine green for treatment of oral mucositis. In the prevention arm, the authors report that the incidence of oral mucositis fell from 66.67% to 6.67%, and in the treatment arm the photodynamic therapy group showed lower scores than the sham control on several scales.
- Who or what was studied
- Pediatric patients with hematologic cancers receiving methotrexate chemotherapy
- Limits stated in the abstract
- The abstract does not report the total number of participants or the sample size per group, so the strength of the evidence cannot be judged from it.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on bmccancer.biomedcentral.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Photodynamic therapy, Oral mucositis, Control group, Laser, Trial registration, Light-emitting diode, Sham. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.